ADH5 and COVID-19: In summary, here, we assessed the therapeutic potential of exogenous GSNO and GSNOR inhibitor (N6022) on disease markers observed in human COVID-19 cases using a SARS-CoV-2 SP-S1-induced mouse model of COVID-19-associated acute lung disease.